Cytotoxic T lymphocytes (CTLs) are important effector cells of graft-versus-host disease (GVHD) and vascular endothelial cells are target cells of allospecific CTL. A combined assessment of T-cell activation and endothelial injury should result in a specific and sensitive test for GVHD. We examined circulating T lymphocytes for effector molecules involved in CTL-mediated endothelial injury. We analyzed CD4 and CD8 T lymphocytes of 24 long-term survivors of allogeneic stem cell transplantation with or without GVHD, and nine healthy, age-matched controls for signs of CTL activation and endothelial injury. IFN-c transcript levels in CD8 T cells were significantly elevated in SCT recipients with GVHD compared to patients without GVHD (767 CD3e units/T cell (376-2050) vs 211 CD3e units/T cell (159-274), P ¼ 0.01). Fas ligand transcript levels in CD4 T cells were significantly elevated in SCT recipients without GVHD compared to patients with GVHD (20 CD3e units/T cell (0-78) vs 0 CD3e units/T cell (0-0), P ¼ 0.01). Von Willebrand factor plasma levels were high in patients with GVHD, but normal in patients without vs 120 (100-141), P ¼ 0.0005). This assessment of T-cell activation and endothelial injury results in a sensitive and specific test to identify patients with active chronic GVHD.
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Chronic graft-versus-host disease (GVHD) occurs in up to 60-70% of patients after allogeneic stem cell transplantation (SCT) 1 and is a major cause of death in long-term survivors of allogeneic SCT. 2 On the other hand, an ongoing alloimmune response can eliminate residual malignant cells in patients suffering from leukemia, and low-grade GVHD improves survival after allogeneic SCT in these patients. 3 Therefore, routine use of immunosuppressive drugs is of questionable value in patients after SCT: it may prevent severe GVHD and also reduce beneficial graft-versus-leukemia effects. Ideally, a noninvasive test to determine GVHD activity could identify patients who qualify for a reduction or an increase of immunosuppressive treatment.
Alloreactive CTL are important effector cells of GVHD 4 and the pretransplant precursor CTL levels predict the development of acute, severe GVHD. 5 Allospecific CTL have been detected in the peripheral blood of patients with acute as well as chronic GVHD. 6 However, MHC tetramers and peptides derived from minor histocompatibility antigens suitable for the detection of circulating, allospecific effector T cells are not available for a majority of allogeneic SCT recipients. We hypothesized that the activation state of circulating CTL would be different in SCT recipients with active GVHD compared to patients without GVHD. We measured the number of circulating CD8 þ and CD4 þ T cells in long-term survivors of SCT with and without manifestations of chronic GVHD and compared it to normal controls. We specifically scrutinized circulating T cells for effector molecules involved in cytolysis, namely perforin, a component of the granule exocytosis pathway and fas ligand (FasL), a component of the contactmediated pathway and for IFN-g, a cytokine produced by CTL in response to antigen. We have recently reported that cutaneous chronic GVHD is characterized by progressive loss of dermal microvessels and that von Willebrand factor (vWF) plasma levels reflect the degree of active T-cellmediated endothelial injury. 7 Therefore, we also measured plasma vWF levels at the same time as T-cell activation. We find that combining this marker of endothelial injury with an assessment of T-cell activation provides a specific, mechanism-based test for active GVHD.
Patients and methods

Patients after allogeneic SCT and healthy control subjects
The patients included in this study underwent allogeneic SCT at the Department of Hematology, University Hospital Basel, between February 1988 and March 2001.
The majority of SCT recipients and the healthy control subjects analyzed in this study have been described previously. 7 Six additional patients with chronic GVHD were included in the present study. The patient characteristics are given in Table 1 . All investigations involving patients and healthy subjects were approved by the institutional ethical review board. In all, 15 adult patients with GVHD (mean age 41715 years: three with late-onset acute, five with extensive and seven with limited chronic disease) were examined in this study. GVHD was diagnosed by the treating physicians according to standard clinical criteria. 8 Nine SCT recipients (mean age 3579 years) who had no GVHD were selected to match the chronic GVHD patients with respect to age and time after SCT. In all, 11 patients with GVHD were on immunosuppressive drugs, whereas the long-term survivors without GVHD were off immunosuppression. Four patients developed GVHD after immunosuppressive treatment was stopped, and blood was taken before it was reinitiated. Nine healthy, age-matched volunteers (mean age 4078 years) were included as controls. All recipients of allogeneic SCT with one exception (UPN 782, see Table 1 ) received HLA-matched stem cell transplants, and all patients showed complete donor chimerism at the time of investigation. After informed consent was obtained, venous blood was collected and anticoagulated with adenosine-citrate-dextrose solution (RDB8652, Baxter, Maurepas, France). Differential leukocyte counts were determined by coulter counting. After venipuncture peripheral blood mononuclear cells (PBMC) were immediately separated from anticoagulated blood by Ficoll density-gradient centrifugation (Lymphoprep, Nycomed, Oslo, Norway), suspended in fetal calf serum (FCS) containing 10% dimethylsulfoxide and stored in liquid nitrogen until subsequent analyses were performed. EDTA plasma was obtained and centrifuged for 20 min at 2000 g, with plasma stored at À701C.
FACS analysis
PBMC were thawed, washed once in PBS-1% BSA (Fluka, Buchs, Switzerland) and distributed at 100 000 cells per tube for surface molecule and intracellular cytokine staining. In order to activate T cells, PBMC were incubated in RPMI-1640 containing 10% FCS, 2 mm l-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (all from GIBCO/Invitrogen, Basel, Switzerland) for 4 h at 371C in the presence of 10 ng/ml phorbol myristate acetate (PMA) and 2 mm ionomycin. At 1 h after the incubation was started, brefeldin A (Sigma, Buchs, Switzerland) was added to the culture medium. The optimal concentrations of the PMA and ionomycin were determined by a dose-response curve for IFN-g expression (data not shown). All immunostainings were carried out on ice. Cells were fixed in ice-cold 4% paraformaldehyde (Sigma, Buchs, Switzerland) in PBS (pH 7.4) for 20 min. After washing with PBS-1% BSA, cells were permeabilized for 10 min in PBS-1% BSA containing 0.1% saponin (Sigma). Cells were then incubated for 30 min with an FITC-conjugated antibody against CD3e, perforin, IFN-g and FasL and PE-conjugated antibody against CD8 or CD4 (Becton Dickinson, Allschwil, Switzerland), respectively. For the detection of naı¨ve, effector and memory CD8 T cells, nonpermeabilized cells were stained with antibodies against CD45RA (FITC conjugate), CD27 (phycoerythrin conjugate) and CD8 (biotin conjugate, detected with streptavidin red 670) and the fraction of CD45RA þ /CD27À and CD45RAÀ/ CD27 þ CD8 T cells were determined. 9 Data were acquired on a FACScalibur (Becton Dickinson) and data analysis was performed using WINMDI version 2.8 (The Scripps Research Institute, La Jolla, CA, USA). The lymphocyte and monocyte populations were gated according to their typical distribution in the FSC/SSC mode. Cells in the lymphocyte gate were further analyzed for T-cell molecule expression.
Quantitative competitive RT-PCR
CD8 þ and CD4 þ T lymphocytes were isolated from PBMC by positive selection. Up to 2.5 Â 10 7 PBMC were incubated with 2 Â 10 7 CD8 dynabeads (M450 CD8, Dynal, Oslo, Norway) for 30 min at 41C. The beads were washed three times with ice-cold RPMI-1640-5% FCS (GIBCO). The nonbinding cells in the supernatant were collected and incubated with 2 Â 10 7 CD4 dynabeads for 30 min at 41C. Beads were again washed three times with RPMI-5% FCS. RNA was extracted using TRI Reagent (MRC, Cincinnati, OH, USA) according to the manufacturer's instructions. Generally, 1 mg RNA was reverse transcribed in the presence of 30 U RNAsin (Promega, Madison, WI, USA) using 200 U M-MLV reverse transcriptase (Promega) and 0.5 mg oligo-dT(15) as primers. The reaction mixture was incubated for 60 min at 451C. The template RNA strand was digested with RNAse H (Promega) for 20 min at 371C. Quantitative competitive RT-PCR of CD3e, perforin, FasL and IFNg was performed as previously described. 10 Briefly, a known amount (100-0.001 fg/ml) of competitor cDNA of each of the T-cell genes analyzed was added to the PCR mix. Amplification was performed by gene-specific primers using Taq polymerase (Promega). The PCR products were separated on a 1.5% agarose gel, stained with ethidium bromide and visualized by UV transillumination. Digital pictures were acquired and PCR band intensity was quantified using NIH image software (version 1.61). The measured amount of genespecific cDNA was normalized to CD3e transcript levels that were arbitrarily set to be 100 000 U. 11 
vWF ELISA
Circulating vWF antigen was measured in EDTA plasma using a commercially available ELISA kit (Corgenics, Westminster, CO, USA) according to the manufacturer's instructions. As a standard curve, serial dilutions of normal pool plasma were used and values were expressed as a percentage of undiluted normal pool plasma.
Statistical analysis
The various groups were compared by the Mann-Whitney U-test. P-values o0.05 were considered statistically significant. The group average is usually represented as the median value and the interquartile range is shown in brackets unless stated otherwise.
Results
Lymphocyte counts and T-cell subsets in long-term survivors of SCT
In long-term survivors of allogeneic SCT, total lymphocyte counts were not profoundly affected by the procedure. Long-term survivors of SCT without GVHD had normalized CD4 T-cell counts compared with healthy controls (0.6 Â 10 /l (0.27-0.78)), which was not statistically different from healthy controls due to the broad range of the CD8 T-cell counts. Taken together, SCT recipients without GVHD had normalized CD4 T-cell counts and persistent expansion of the circulating CD8 T-cell pool. Patients with GVHD show persistent reduction in the size of the circulating CD4 T-cell pool and a highly variable number of CD8 T-cell counts. T-cell subset enumeration on its own was not sufficiently sensitive or specific to discriminate between SCT recipients with and without GVHD.
Phenotype characterization of CD8 þ cytotoxic T cells in long-term survivors of SCT CD8 þ cytotoxic T lymphocytes (CTLs) have been shown to be important effector cells of GVHD. 4 Perforin and IFN-g are synthesized and released by activated effector CTL. We examined the circulating CD8 T-cell pool for the presence of perforin-positive cells and for cells capable of secreting IFN-g. Perforin was readily detectable in unstimulated, circulating CD8 T cells of healthy controls and SCT recipients ( Figure 2a) ; without in vitro stimulation, less than 1% of the CD8 T cells contained detectable IFN-g protein. For all our patients, the precise antigen involved in the graft-versus-host reaction was unknown and pretransplant blood samples from SCT recipients as a source of antigen-presenting cells were not available. Cellular IFN-g protein became measurable after pharmacological stimulation with the kinase C activator PMA and the calcium ionophore ionomycin (Figure 2b) . We also quantified the fraction of naı¨ve, memory and effector CD8 T cells by costaining CD8 þ T cells for CD45RA and CD27 expression.
9 Figure 2c shows a representative experiment performed with PBMC from a control subject (left), from an SCT recipient without GVHD (middle) and from an SCT recipient with GVHD (right). The fraction of perforin-positive CD8 T cells was significantly greater in long-term survivors of SCT compared with healthy controls (Figure 3a , 78% (58.3-87.8) vs 42% (37.3-53.2), P ¼ 0.0005). The same difference was observed for the combined fraction of effector and memory CD8 T cells (Figure 3c , 57.8% (50.5-68) vs 43.8% (40.2-50.1), P ¼ 0.01). However, the fraction of CD8 T cells that synthesized IFN-g after pharmacological stimulation was the same in all groups analyzed (Figure 3b ). Neither perforin protein positivity nor the combined fraction of effector and memory CD8 T cells discriminated between SCT recipients with and without GVHD (Figure 3a and c) . Taken together, the procedure of allogeneic SCT leads to an expansion of the effector and memory CD8 T-cell pool irrespective of the presence or absence of active GVHD. Pharmacological activation of IFN-g secretion by PMA/ ionomycin is not a useful test to identify activated CD8 T cells in circulation.
CTL gene transcript levels in T-cell subsets of long-term survivors of SCT
Since protein measurements were either unspecific (in the case of perforin) or not sensitive enough (in the case of IFN-g) to detect activated CTL in the circulation of patients with GVHD, we extended our analysis to measure transcript levels of a series of candidate genes known to be expressed by activated CTLs.
10 Figure 4 shows a representative competitive PCR experiment performed to measure quantitatively the cellular levels of IFN-g and FasL mRNA. The absolute values of transcript levels were normalized to the amount of CD3e that was arbitrarily set to be 100 000 U. The absolute CD3e gene transcript levels were generally higher after allogeneic SCT. In CD8 T cells, the difference between healthy controls and SCT recipients was 896 Â 10 À21 g/T cell (281-1609) vs 1907 Â 10 À21 g/T cell (1203-3558), P ¼ 0.05. In CD4 T cells, the difference between healthy controls and SCT recipients was 980 Â 10 À21 g/T cell (244-1642) vs 1400 Â 10 À21 g/T cell (720-2672), this difference being not statistically significant. CD3e transcript levels between patients with or without GVHD was the same in CD8 and CD4 T cells (data not shown). Figure 5 shows cellular transcript levels of IFN-g in CD8 T cells and of FasL in CD4 T cells, respectively. In contrast to the protein measurements, IFN-g transcript levels in CD8 T cells were significantly higher in SCT recipients with GVHD compared to those without GVHD (Figure 5a ). The IFN-g transcript levels did not correlate with the fraction of IFN-g-positive T cells obtained after pharmacological stimulation.
We wondered whether elevated IFN-g transcript levels in CD8 T cells could be the consequence of viral infections occurring after allogeneic SCT. Five patients with GVHD (33%) and seven patients without GVHD (78%) suffered from viral infections after SCT (see Table 1 ). Unexpectedly, higher IFN-g transcript levels were found in SCT transplant recipients who had no viral infections (for CD8 T cells: 1299 CD3e units/T cell (274-2955)) compared to those with viral infections (for CD8 T cells: 317 CD3e units/ T cell (152-422), not significant). FasL transcript levels were also measured quantitatively. In both CD8 and CD4 T cells, FasL transcript levels were higher in SCT recipients without GVHD than in patients with GVHD. In CD8 T cells, this difference was not significant (100 CD3e units/ T cell (34-399) vs 54 CD3e units/T cell (5-169)), but did reach statistical significance for CD4 T cells (Figure 5b ). It should be pointed out that SCT recipients without GVHD are the only patient group in our study in whom FasL transcript levels were uniformly detectable in circulating A mechanism-based approach to assess GVHD activity CD4 T cells. FasL protein was not detectable in circulating T cells and could not be induced by pharmacological stimulation. Furthermore, IL-10, a cytokine expressed by regulatory T cells was not detected in CD4 T cells of patients with positive FasL transcript levels (data not shown).
Immunosuppressive treatment could affect the transcription levels of T-cell effector genes such as IFN-g or FasL.
We therefore analyzed four patients with clinically active GVHD, but without immunosuppressive treatment at the time of investigation. The results obtained from these GVHD patients are represented separately (solid vs shaded triangles). The data suggest that immunosuppressive treatment by itself does not influence FasL or IFN-g gene transcript levels.
A mechanism-based approach to assess GVHD activity As a noninvasive test of ongoing target tissue injury, 7 vWF levels were measured in these patients. vWF was normal in SCT recipients without GVHD but elevated in patients with GVHD ( Figure 6 ). We next scored the patients for elevated vWF levels, elevated IFN-g transcript levels in CD8 T cells and absent FasL expression in CD4 T cells ( Table 2 ). The 75th percentile of healthy controls served as a cutoff value for the scoring procedure. A combined score number of three was assigned when target tissue injury (as identified by elevated vWF levels) was detectable, IFN-g-producing, -activated CD8 T cells were present and FasL-expressing, regulatory CD4 T cells were absent. In this case-control study, this score identified patients with GVHD with a sensitivity of 94% (95% CI 68-100%) and a specificity of 100% (95% CI 78-100%).
Discussion
Peptide-loaded, MHC class I tetramers have been used to monitor circulating, antigen-specific cytotoxic T cells in the course of various viral and bacterial infections as well as in acute and chronic GVHD. 6, 12, 13 Although the repertoire of diagnostic tools available to detect the common, MHC class I-restricted, CD8-dependent T-cell responses is quite complete for certain viral infections such as HIV, EBV or hepatitis C, [14] [15] [16] there is still a majority of bone marrow transplant recipients for which the antigen profile eliciting a CTL-mediated immune response is largely unknown. The tetramer technology is not developed yet to detect a panoply of minor histocompatibility antigen-specific T cells. Our data demonstrate that in SCT recipients, the activation pattern of circulating T lymphocytes can be used to identify patients with active GVHD. We examined SCT recipients for T-cell numbers, the protein phenotype of circulating CD8 þ T cells and the transcriptional phenotype of a selection of CTL genes in both CD8 and CD4 T cells. We found that for the individual patient, the transcriptional phenotype was the most sensitive test to detect active GVHD. Combined with signs of ongoing endothelial injury, it describes a disease activity score with The competitor concentration at which both bands reach equal intensity is taken as the cDNA concentration in the T-cell sample analyzed. The measured amount was normalized to the concentration of CD3e in the same sample, which was arbitrarily set to be 100 000 units. high sensitivity and specificity for GVHD. In a similar case-control study of patients after kidney transplantation, Strehlau et al 17 found that intrarenal transcript levels of FasL, perforin and granzyme B had a high sensitivity and specificity to identify patients with acute rejection. Our results suggest that GVHD activity can be reliably assessed by the transcriptional phenotype of circulating lymphocytes. We do not know yet whether transcript levels in circulating T cells are an early indicator of preclinical disease. This question will be addressed in an ongoing, prospective study. In addition, a transcript analysis that is focused on cytotoxic T-cell genes may not be able to discriminate between a CTL-driven immune response against viral diseases and an alloimmune reaction involved in GVHD. 18 The strength of this test is to assess the activity of chronic GVHD with the intention to adapt the intensity of immunosuppressive treatment. The diagnosis of a viral infection will continue to rely on the detection of a specific microorganism.
The analysis of CTL gene transcript levels in CD4 and CD8 T cells suggest a specific role for FasL in the prevention of GVHD. The fact that patients without GVHD were the only subjects examined in which FasLexpressing CD4 T cells were regularly found in circulation suggests that these cells could be involved in the suppression of disease. Future studies will be needed to characterize these cells, specifically to determine if they are acting as CD4 þ regulatory T cells.
The release of vWF is a sensitive marker of endothelial activation and injury, but elevated plasma levels are not specific for endothelial death. Circulating, necrotic endothelial cells can be found in the blood from patients with small vessel vasculitis, and in this case, the absolute number correlates well with disease activity. 19 The identification of a more specific blood test for endothelial death may further improve this molecular, mechanism-based disease activity score. P=0.0005 Figure 6 Endothelial injury in SCT recipients with GVHD. vWF was measured in citrated plasma by ELISA. Serial dilutions of normal pool plasma served as a standard curve. Nondiluted normal pool plasma was set to contain 100% vWF. SCT recipients with and without GVHD were compared using the Mann-Whitney U-test, and P-values o0.05 are shown. 
